Beta Bionics Stock

In the wake of earning FDA clearance for its insulin pump and automated dosing software—which connect to a Dexcom continuous glucose monitor to create what’s known as a hybrid closed-loop system for diabetes management—Beta Bionics is raking in the dough. The Massachusetts-based company has pooled $100 million in series D equity funding, it announced this week.

Artificial pancreas systems synchronize an insulin pump and continuous glucose monitor with the goal of delivering an almost completely hands-off approach to diabetes management—and the newest one cleared by the FDA aims to make that goal even easier to achieve.

The iLet is a pocket-sized, wearable investigational medical device that autonomously controls blood sugar in people with diabetes and other conditions --...